Heart Failure - Pipeline Review, Q4 2010

Global Markets Direct, December 2010, Pages: 96

Heart Failure - Pipeline Review, Q4 2010

Summary

Global Markets Direct’s, “Heart Failure Pipeline Review, Q4 2010”, provides an overview of the Heart Failure therapeutic pipeline. This report provides information on the therapeutic development for Heart Failure , complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Heart Failure . “Heart Failure -Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- A snapshot of the global therapeutic scenario for Heart Failure   .
- A review of the Heart Failure    products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Heart Failure    pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- A snapshot of the global therapeutic scenario for Heart Failure   .
- A review of the Heart Failure    products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Heart Failure    pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Heart Failure Overview
Therapeutics Development
An Overview of Pipeline Products for Heart Failure
Heart Failure Therapeutics under Development by Companies
Heart Failure Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Companies Involved in Heart Failure Therapeutics Development
Cardium Therapeutics, Inc.
Baxter International Inc.
Johnson & Johnson
Biogen Idec Inc.
Amgen Inc.
Eli Lilly and Company
GlaxoSmithKline plc
Targeted Genetics Corporation
Bioheart, Inc.
deCODE genetics, Inc.
Neurocrine Biosciences, Inc.
Aldagen, Inc.
Novartis AG
Acorda Therapeutics, Inc.
Warner Chilcott Limited
Angioblast Systems, Inc.
Bayer AG
Geron Corporation
Genfit
Medicure Inc.
Compugen Ltd.
Palatin Technologies, Inc.
Cardio3 BioSciences SA
Unigene Laboratories, Inc.
Titan Pharmaceuticals, Inc.
POZEN Inc.
Torrent Pharmaceuticals Limited
Hanall Pharmaceutical Co., Ltd.
Protemix Corporation Limited
NormOxys, Inc.
ARCA biopharma, Inc.
GenKyoTex S.A.
AmKor Pharma, Inc.
Cordex Pharma, Inc.
Asklepios BioPharmaceutical, Inc.
Regulus Therapeutics Inc.
miRagen Therapeutics, Inc.
Sorbent Therapeutics, Inc.
Biopeutics co., Ltd.
Universities/Institutes Involved in Heart Failure Therapeutics Development
Heart Failure Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
BG9719 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
C-Cure - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carvedilol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carvedilol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gencaro - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LCZ696 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MyoCell - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PA32540_ - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Papeilin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles – Universities/Institutes
Acetazolamide + Buspirone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aspirin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Beta adrenergic blockers + Platelet inhibitors + ACE Inhibitors - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bisoprolol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bone Marrow Derived Adult Stem Cells + G-CSF - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carvedilol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Clopidogrel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Enalapril - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Erythropoietin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Iron-Sucrose - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Levosimendan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Levosimendan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Metformin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Omacor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rosuvastatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Saizen - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sildenafil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
spironolactone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Spironolactone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Warfarin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Discontinued Products
Heart Failure - Featured News
Dec 09, 2010: Acorda Initiates Phase I Heart Failure Clinical Trial With GGF2
Nov 17, 2010: Cardio3 BioSciences Announces Positive Outcome Of C-Cure Phase II Clinical Trial In Heart Failure Patients
Nov 15, 2010: Celladon Announces 12-Month Data From Phase II CUPID Clinical Trial Of MYDICAR In Advanced Heart Failure Patients
Oct 07, 2010: ARCA Enters SPA Agreement With FDA For Bucindolol Development In Heart Failure Population
Sep 21, 2010: Cytokinetics Provides Update Regarding Omecamtiv Mecarbil Clinical Development Program
Sep 14, 2010: Cytokinetics Presents Phase I Clinical Trial Data On Omecamtiv Mecarbil At 2010 Heart Failure Society Of America Annual Meeting
Sep 13, 2010: Trevena Presents Preclinical Data For TRV120027 At 2010 HFSA Meeting
Aug 26, 2010: Cardioxyl Initiates Phase IIA Study Of CXL-1020 In Heart Failure Patients
Aug 16, 2010: Cardio3 BioSciences Publishes Science Basis For C-Cure In JACC
Aug 02, 2010: Cardioxyl Announces Positive Results From First Clinical Study Of CXL-1020 In Heart Failure Patients
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• Substance (Drug) Abuse – Pipeline Review, H1 2013
• Pandemic Influenza – Pipeline Review, H1 2013
• Brain Tumor – Pipeline Review, H1 2013
• Drug Addiction – Pipeline Review, H1 2013
• Nausea – Pipeline Review, H1 2013
• Bone Disorders – Pipeline Review, H1 2013
• Ebola Viral Infections – Pipeline Review, H1 2013
• Smoking Cessation – Pipeline Review, H1 2013
• Liver Transplantation – Pipeline Review, H1 2013
• Skin And Skin Structure Infections (SSSI) – Pipeline Review, H1 2013